You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

Investigational Drug Information for BIIB074


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug BIIB074?

BIIB074 is an investigational drug.

There have been 18 clinical trials for BIIB074. The most recent clinical trial was a Phase 2 trial, which was initiated on April 19th 2023.

The most common disease conditions in clinical trials are Neuralgia, Trigeminal Neuralgia, and Bipolar Disorder. The leading clinical trial sponsors are Biogen, GlaxoSmithKline, and Convergence Pharmaceuticals.

There are eighteen US patents protecting this investigational drug and two hundred and twenty-four international patents.

Recent Clinical Trials for BIIB074
TitleSponsorPhase
802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal NeuralgiaBiogenPhase 3
802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal NeuralgiaBiogenPhase 3
Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic PolyneuropathyBiogenPhase 1

See all BIIB074 clinical trials

Clinical Trial Summary for BIIB074

Top disease conditions for BIIB074
Top clinical trial sponsors for BIIB074

See all BIIB074 clinical trials

US Patents for BIIB074

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BIIB074 ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
BIIB074 ⤷  Sign Up Methods and compositions for decreasing gastric emptying Purdue Pharma L.P. (Stamford, CT) ⤷  Sign Up
BIIB074 ⤷  Sign Up Erythromelalgia treatment Convergence Pharmaceuticals Limited (Maidenhead, GB) ⤷  Sign Up
BIIB074 ⤷  Sign Up Process for preparing alpha-carboxamide pyrrolidine derivatives Convergence Pharmaceuticals Limited (GB) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BIIB074

Drugname Country Document Number Estimated Expiration Related US Patent
BIIB074 Australia AU2017261372 2036-05-05 ⤷  Sign Up
BIIB074 Canada CA3023278 2036-05-05 ⤷  Sign Up
BIIB074 China CN107847398 2036-05-05 ⤷  Sign Up
BIIB074 European Patent Office EP3452003 2036-05-05 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.